ADPT
Closed
Adaptive Biotechnologies Corp
11.19
-0.46 (-3.95%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 11.65
Day's Range: 11.17 - 11.595
Send
sign up or login to leave a comment!
When Written:
8.8
Adaptive Biotechnologies Corp is a biotechnology company that focuses on developing and commercializing immune-driven therapies for diseases such as cancer, autoimmune disorders, and infectious diseases. The company uses its proprietary immune profiling technology, called ImmunoSeq, to analyze the immune system of patients and identify specific T-cell receptors that can be used to develop personalized therapies.
Adaptive Biotechnologies was founded in 2009 in Seattle, Washington, and went public in 2019. The company has partnerships with pharmaceutical companies such as Genentech, Amgen, and Microsoft, and has collaborations with academic institutions and research organizations.
In addition to its work on immune-driven therapies, Adaptive Biotechnologies also provides clinical diagnostic services, such as its ClonoSEQ assay, which is used to detect minimal residual disease in patients with certain blood cancers.
As of 2021, Adaptive Biotechnologies has a market capitalization of over $8 billion and employs over 900 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Adaptive Biotechnologies was founded in 2009 in Seattle, Washington, and went public in 2019. The company has partnerships with pharmaceutical companies such as Genentech, Amgen, and Microsoft, and has collaborations with academic institutions and research organizations.
In addition to its work on immune-driven therapies, Adaptive Biotechnologies also provides clinical diagnostic services, such as its ClonoSEQ assay, which is used to detect minimal residual disease in patients with certain blood cancers.
As of 2021, Adaptive Biotechnologies has a market capitalization of over $8 billion and employs over 900 people.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!